Intestinal Behçet disease (BD), which is an immune-mediated, chronic, inflammatory intestinal disease, can be difficult to treat, in part because the pathogenesis of intestinal BD is unclear. However, as data for using anti–tumor necrosis factor (anti-TNF) drugs have been accumulating in the treatment of inflammatory bowel disease (IBD), which has a similar clinical presentation, the potential to treat BD with these agents is under investigation.
Intestinal Behçet's Disease (BD), which is an immune-mediated, chronic, inflammatory intestinal disease, can be difficult to treat, in part because the pathogenesis of intestinal BD is unclear. However, as data for using anti—tumor necrosis factor (anti-TNF) drugs have been accumulating in the treatment of inflammatory bowel disease (IBD), which has a similar clinical presentation, the potential to treat BD with these agents is under investigation.
A recently published review, appearing in Gut and Liver, explains the current knowledge base concerning anti-TNF agents in intestinal BD.
Infliximab, say the authors, was first shown to be effective in treating patients with intestinal BD who were steroid-dependent in 2001. Patients in that study had healing of their ulcers within 10 days and sustained remission for 12 months. Another study showed that infliximab plus methotrexate led to improvement in as little as 2 weeks. The first phase 3 trial in patients with intestinal BD resulted in rates of complete response of 55%, 55%, and 60% at weeks 14, 30, and 54, respectively, and a second phase 3 trial is ongoing.
Adalimumab has fewer data available in intestinal BD; the first prospective, open-label, single-arm, phase 3 multicenter trial of adalimumab found that complete remission was achieved by 20% of patients at weeks 24 and 52. At weeks 52 and 100, 60% and 40% of patients, respectively, showed a clinical response. Combination of adalimumab and disease-modifying anti-rheumatic drugs (DMARDs) did not appear to be superior to monotherapy. A prospective, multicenter study lasting 50 weeks has been completed but not yet reported, and a phase 3 trial is currently recruiting.
Etanercept has not been the subject of a phase 3 study in intestinal BD, and questions remain as to whether it could prove useful in intestinal BD given its inefficacy in treating IBD. Etanercept has also demonstrated the ability to produce paradoxical IBD in patients undergoing treatment for idiopathic juvenile arthritis.
Golimumab, too, has very few data available in treating intestinal BD. A single retrospective study that assessed the long-term efficacy and safety of golimumab in this indication found that 17 patients with BD—6 of whom had intestinal BD—who received golimumab for poorly controlled disease and treatment failure of at least 1 other biologic agent improved after a mean treatment time of 5 weeks. Combination therapy with DMARDs resulted in better outcomes than did monotherapy.
Certolizumab pegol is the only pegylated anti-TNF agent approved by the FDA. This therapy also has limited data concerning its use in intestinal BD, but a study in 13 patients with BD, 5 of whom had intestinal involvement, resulted in 7 patients exhibiting a satisfactory response.
Because many patients with intestinal BD fail to respond adequately to conventional therapies, say the authors, and because anti-TNF therapy has thus far demonstrated favorable outcomes in this patient population, use of anti-TNF agents should be further studied to clarify the rationale underlying the outcomes of the small studies described in the review.
Reference
Park J, Cheon JH. Anti—tumor necrosis factor therapy in intestinal Bechet’s Disease. [Published online May 24, 2018.] Gut Liver. doi: 10.5009/gnl17462.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.